Optimizing Evidence-based HIV Prevention Targeting People Who Inject Drugs on PrEP

• Status: Not yet recruiting
• Trial end date: 2027-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators will conduct an optimization trial among N=256 PWID newly started on medication for opioid use disorder and Pre-Exposure Prophylaxis (PrEP) to assess the performance of four intervention components (Attention, Executive Functioning, Memory, and Information Processing) aimed at enhancing the ability of PWID on MOUD to process and utilize HIV prevention content, leading to improvements in HIV prevention information, motivation, behavioral skills, and behaviors (IMB).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Connecticut

Criteria

Inclusion Criteria:

• being 18 years or older

• meeting DSM-V criteria for opioid dependence and being newly prescribed and adherent to Medication for Opioid Use Disorder (e.g., methadone, buprenorphine) at the APT Foundation, Inc.

• showing mild cognitive impairment based on the Montreal Cognitive Assessment (MoCA) screening

• having initiated Pre-Exposure Prophylaxis (PrEP) within the past week

• confirming HIV-negative status through proof of PrEP prescription

• reporting unsafe injection drug use practices or unprotected sex within the past 3 months

• having a cell phone

• being able to read and understand in English

Exclusion Criteria:

• unable to provide consent

• actively suicidal

• actively homicidal

• actively psychotic

• display MoCA scores suggestive of dementia